Nanoparticle Protein Interactions

Nanoparticle Protein Interactions

For the delivery of bioactive compounds such as therapeutic proteins/peptides siRNA or drugs to a specific cell or organ, it is not only of great importance to improve the stability of the therapeutic agent during passage through the blood stream, but also to extend the circulation time in the body. Consequently the interaction with blood components has to be controlled to limit aggregation processes. Furthermore uptake in blood cells like macrophages has to be minimized. Only then the drug can reach the target cells.

A major focus is currently put on the defined analysis of the interaction of nanoparticles/nanocapsules with high concentrated protein solutions like blood plasma or cytosol as well as with isolated proteins. Control of protein adsorption onto nanomaterials is especially important in the biomedical area. Our goal is the defined analysis of protein-polymer interactions by applying a combination of different physicochemical techniques to include dynamic and static light scattering (DLS/SLS), isothermal titration calorimetry (ITC), high performance liquid chromatography coupled with mass spectrometry (LC-MS), asymmetric field flow fractionation (AF-FFF) and circular dichroism (CD) spectroscopy. Combination of these analytical methods allows us to address multiple aspects of protein-polymer interactions. We are one of a few research groups worldwide that are capable of performing multi-angle DLS on concentrated human blood plasma as a routine measurement to monitor aggregation events between nanoparticles and human blood plasma. Mass spectrometry (with the group of T. Weil and with S. Tenzer from the University Medical Center Mainz) was used for the identification of adsorbed proteins on nanocapsules and for the first time for the determination of the adsorption kinetics. Using ITC we are first able to monitor the thermodynamics of the interactions between nanocapsules and whole blood plasma as well as specific proteins.

Understanding the details of the formation and the composition of the protein corona and also the consequences that are incurred by the specific proteins needs to be investigated further. The defined analysis of nanoparticle interactions might allow pre-selection of nanoparticles for in vivo application.

Related Links

Dr. Svenja Morsbach
Our group focuses on (bio-)polymer characterization as well as understanding and controlling biomolecule interactions with nanomaterial surfaces. more
Dr. Volker Mailänder
The Mailänder group is focusing on translating drug nanocarriers into clinically relevant applications by understanding their potentials and hurdles. more
Go to Editor View